A phase I dose-escalation clinical trial of SB-509-0401 [SB 509] in subjects with diabetic neuropathy

Trial Profile

A phase I dose-escalation clinical trial of SB-509-0401 [SB 509] in subjects with diabetic neuropathy

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs SB 509 (Primary)
  • Indications Diabetic neuropathies
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Dec 2008 Full data set presented at a Sangamo BioSciences Investor and Analyst briefing
    • 15 Sep 2008 Positive 180-day results presented at the 44th EASD, according to a Sangamo media release.
    • 06 Jun 2008 Status changed from recruiting to completed according to Sangamo BioSciences.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top